Biotechnology Companies in the News – July 2011

Published in Biolines July 2011

Editor’s Note: The home page of the BioNJ Web site provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page (www.BioNJ.org) to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to send their news releases to BioNJ via e-mail at BioNJ@BioNJ.org.

July 20

Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C

Dr. Ashok Amin Joins Advaxis as Vice President of Research and Development

Data on Bristol-Myers Squibb’s Investigational Treatment for Alzheimer’s Disease Demonstrate Potential Therapeutic Window at Doses Below 100 mg in Phase II Safety and Tolerability Study

July 19

Immunomedics Awarded Additional Patent for PEGylation Method

Tobira Therapeutics Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults

20,000 Patients Successfully Implanted with AIGISRx® Antibacterial Envelope for Pacemakers and Defibrillators

July 18

LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.

J&J Divests Prescription Skin Care Company in $345M deal

July 15

LEO Pharma A/S and The Scripps Research Institute Enter Collaboration

July 14

Bard to Host Earnings Conference Call on July 21, 2011

YERVOY™ (ipilimumab) Approved for the Treatment of Previously-Treated Advanced Melanoma in the EU

July 13

Celgene Corporation to Announce Second Quarter 2011 Results on July 28, 2011

The Medicines Company to Announce Second Quarter 2011 Financial Results on Wednesday, July 27, 2011

July 11

Merck to Participate in New Research Efforts to Eradicate HIV

Advaxis Completes Enrollment of Low Dose Cohort in CIN Study

Watson and Antares Announce Exclusive License Agreement for Antares’ Oxybutynin Gel Product (Anturol®)

July 7

CorMedix Submits Design Dossier for Neutrolin® (CRMD003) to Start European Approval Process

Bristol-Myers Squibb to Announce Results for Second Quarter 2011 on July 28

July 6

Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement for an Investigational Immuno-Oncology Biologic

Health Plans Continue to Favor Longer-Marketed Brands for Immune Biologics Therapies

Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Company’s Board of Directors

PediatRx Obtains State Licenses and Begins Direct Sales to Wholesalers and Distributors through ICS

Celldex Expands Senior Management Team with Appointment of Dr. Ronald A. Pepin, Senior Vice President and Chief Business Officer

Sophion becomes member of Biolin Scientific group of companies

Pharmasset Enters into a Clinical Collaboration Agreement with Tibotec Pharmaceuticals for a Combination Study in Patients Chronically Infected with Hepatitis C

July 5

Amneal Pharmaceuticals Executives Named Ernst & Young Entrepreneur Of The Year® 2011 New Jersey Award Winners

Innovative Curriculum Helps Teachers Meet NJ Standards for 21st Century Essential Work Force Skills

July 1

Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal

June 30

Paragon Solutions and BioClinica Reveal Findings from First Clinical Trial Supplies Industry Forecasting Survey

Advaxis Granted Pre-IND Meeting with the FDA for Advaxis-PSA Prostate Immunotherapy

June 29

AstraZeneca and PTC Therapeutics Announce Strategic Oncology Drug Discovery Collaboration with Potential Extension to Other Therapeutic Areas

Catalent Pharma Solutions Appoints New Medication Delivery Solutions President

Chris L. French Joins Advaxis as Executive Director of Medical Affairs

Alliance Life Sciences Releases White Paper: Impact of Accountable Care Organizations on Life Sciences Manufacturers

Amicus Therapeutics Announces John F. Crowley to Return as Chairman and Chief Executive Officer

June 28

UPS and Merck Expand Their Distribution and Logistics Agreement

June 27

Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects

Juvenile Diabetes Research Foundation to Fund Collaboration between University of Michigan and PCAsso Diagnostics LLC.

Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes

Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors

Immunomedics Receives Third Milestone Payment from Nycomed

Unigene Presents Positive Advanced Preclinical Data for UGP281 a Potent, Orally Delivered Anorexigenic Peptide in a Late-Breaking Poster Presentation at the American Diabetes Association 71st Scientific Sessions

Pharmaceutical Industry Veterans Establish BioEndpoint Consulting to Offer Strategic Insight and Expertise in Commercialization Processes and Drug Development

Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer

CORRECTING and REPLACING Janssen Pharmaceutical Companies of Johnson & Johnson at 2011 BIO International Convention, June 27 – 30, 2011

ViroStatics CEO Franco Lori, MD to Present Novel Immune-based Technologies for HIV/AIDS and Chronic Diseases at the 2011 BIO International Conference

Amicus Therapeutics Joins Russell 3000® Index

June 24

Laureate’s Electronic Submission Gateway Approved

Columbia Laboratories Added to Russell 3000 Index

NovaDel Pharma Inc. to Present at 2011 BIO International Convention

http://www.bioportfolio.com/news/article/723454/Novadel-Pharma-Inc-To-Present-At-2011-Bio-International-Convention.html

Aegerion Pharmaceuticals Announces Pricing of Public Offering

June 23

CorMedix Provides Regulatory Update for CRMD003 (NEUTROLIN®)

Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue

June 22

Pharmasset Announces Issuance of U.S. Patent for PSI-7977

ELIQUIS® (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study

Tobira Therapeutics Initiates Phase IIb Trial of Cenicriviroc, a Novel CCR5/CCR2 Antagonist for the Treatment of HIV Infection

June 20

Derma Sciences Raises $29 Million in Private Placement Financing